Information Provided By:
Fly News Breaks for February 15, 2019
ACRX
Feb 15, 2019 | 07:14 EDT
Credit Suisse analyst Vamil Divan started AcelRx with an Outperform rating and $7 price target, stating that he sees the company as well-positioned to capture market share with its Dsuvia treatment for pain. He also notes the potential for a Zalviso NDA submission in 2019.
News For ACRX From the Last 2 Days
There are no results for your query ACRX